Not FDA approved and sold as a research chemical. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

GHRP-2

Not FDA approved

Growth hormone secretagogue

Also known as: pralmorelin, Pralmorelin, KP-102, pralmorelina, pralmoreline, KP 102, Ala-beta-Nal-Ala-Trp-Phe-Lys-NH2, pralmorelinum

Evidence score

34/ 100

Emerging evidence

Early evidence, mostly unproven in humans

Regulatory standing. Sold as a research chemical, not approved
Limited human data. Some human data exists, not conclusive
No registered human trials. Nothing registered on ClinicalTrials.gov
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

GHRP-2, also called pralmorelin, is a synthetic peptide in the growth hormone releasing peptide family. It is thought to act on the ghrelin receptor (growth hormone secretagogue receptor) in the pituitary and brain, triggering release of growth hormone and often raising appetite, cortisol, and prolactin as well.

What the evidence shows

Automatic summaryLimited human data

Older published human studies show it can acutely raise growth hormone levels, and it has been used in Japan as a diagnostic test agent, but it is not FDA-approved and no registered human trials are listed. Long-term benefits and safety for any health or performance outcome have not been established in humans.

Key facts

Molecular formula

C45H55N9O6

Molecular weight

818 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

0registered studies

Nonemost advanced phase

0completed (sample)

0recruiting (sample)

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

213papers referencing GHRP-2

Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness.

J Clin Endocrinol Metab1999

Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.

J Clin Endocrinol Metab1998

Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats.

Am J Physiol Endocrinol Metab2005

Growth hormone-releasing peptides.

Eur J Endocrinol1997

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.